Nuvalent, Inc. (NUVL) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $102.32: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.
Nuvalent is a clinical-stage biopharma developing kinase inhibitors for NSCLC. Zidesamtinib (ROS1-selective) has an NDA accepted by FDA with September 18, 2026 PDUFA date for TKI pre-treated patients; neladalkib (ALK-selective) NDA submission is planned H1 2026, and the Phase 3... Read more
Sell if holding. Engine safety override at $102.32: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 4.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Nuvalent, Inc.
Latest news
- Nuvalent Q1 EPS $(1.39) Misses $(1.36) Estimate — benzinga May 7, 2026 negative
- Guardant Health Announces Strategic Collaboration With Nuvalent To Develop And Commercialize Oncology Pipeline On Guarda — benzinga Apr 30, 2026 positive
- Guardant Health And Nuvalent Enter Strategic Collaboration For The Development And Potential Commercialization Of Nuvale — benzinga Apr 30, 2026 positive
- Nuvalent To Present Pivotal Data For Neladalkib From Global ALKOVE-1 Phase 1/2 Clinical Study During Oral Presentation A — benzinga Apr 21, 2026 positive
- HC Wainwright & Co. Reiterates Buy on Nuvalent, Maintains $155 Price Target — benzinga Apr 21, 2026 positive
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezidesamtinib, neladalkib, and NVL-33010-K Item 1A: 'Our future prospects are substantially dependent on zidesamtinib, neladalkib and NVL-330'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $102.32: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $95.16. Score 4.6/10, moderate confidence.
Take-profit target: $127.85 (+25.0% upside). Prior stop was $95.16. Stop-loss: $95.16.
Concentration risk — Pipeline: zidesamtinib, neladalkib, and NVL-330; Quality below floor (1.2 < 4.0).
Nuvalent, Inc. trades at a P/E of N/A (forward -25.3). TrendMatrix value score: 7.5/10. Verdict: Sell.
25 analysts cover NUVL with a consensus score of 4.3/5. Average price target: $142.
What does Nuvalent, Inc. do?Nuvalent is a clinical-stage biopharma developing kinase inhibitors for NSCLC. Zidesamtinib (ROS1-selective) has an NDA...
Nuvalent is a clinical-stage biopharma developing kinase inhibitors for NSCLC. Zidesamtinib (ROS1-selective) has an NDA accepted by FDA with September 18, 2026 PDUFA date for TKI pre-treated patients; neladalkib (ALK-selective) NDA submission is planned H1 2026, and the Phase 3 ALKAZAR trial (vs. alectinib) was initiated July 2025. Both programs are wholly owned with worldwide commercialization rights.